Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL
Data from Phase 3 E1912 study showed previously untreated patients aged 70 years or younger treated with ibrutinib plus rituximab…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.